Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Patients histologically or cytologically diagnosed with advanced malignant solid tumors

• Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies

Exclusion Criteria:

• Central lung lesions involving major blood vessels

• Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)